The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Access to Data and Biospecimens, 2020Development of a Biomarker Platform for Parkinson’s Disease Using Patient-derived Cells
Study Rationale:
Inadequate understanding of how Parkinson's disease develops is a major roadblock in developing effective therapeutics and methods to diagnose the disease earlier. This project... -
Improved Biomarkers and Clinical Outcome Measures, 2020PPMI DATIQ and SR T1w MRI Analysis
Study Rationale:
Parkinson’s disease results in functional and structural changes in the brain. Non-invasive imaging methods such as SPECT and MRI can measure these changes. The dopamine transporter... -
Improved Biomarkers and Clinical Outcome Measures, 2020Predicting Conversion to Parkinson’s Disease Based on Proteomic Biomarkers in a Large Prospective Cohort
Study Rationale:
The ultimate aim in Parkinson’s disease research is to identify individuals at risk for developing Parkinson’s prior to disease onset. To reach this goal, a set of informative markers... -
Improved Biomarkers and Clinical Outcome Measures, 2020Assessment of Brain Tau Burden in Parkinson's Disease with or without a LRRK2 Mutation using [18F]MK-6240 PET Imaging
Study Rationale:
The precise mechanisms of cellular damage in Parkinson's disease remain unclear. Research has shown that abnormal forms of the protein alpha-synuclein accumulates in brain cells in... -
Therapeutic Pipeline Program, 2019Oligomeric Alpha-synuclein-specific Antibody-based Gene Therapy
Study Rationale:
Alpha-synuclein is the primary component of Lewy bodies, the hallmark of Parkinson’s disease (PD). In particular, soluble aggregates of alpha-synuclein, also referred to as oligomers... -
Therapeutic Pipeline Program, 2019Study of a Levodopa Adjunctive Therapeutic without Dyskinesia Liability
Study Rationale:
Evidence suggests that levodopa’s efficacy and side effects (uncontrolled movements called dyskinesia) are caused by activating dopamine D1 receptors. An optimal Parkinson’s disease...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.